SCHEMBL23219226

SCHEMBL23219226

CCOC(=O)Cc1cccc(C#N)c1OCc1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 1/20 0.44
PRMT5 O14744 2/20 0.42
PTGER1 P34995 1/20 0.42
PTGER4 P35408 1/20 0.42
PTGER3 P43115 1/20 0.42
PTGER2 P43116 1/20 0.42
L3MBTL1 Q9Y468 3/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPK1 P28482 1/20 0.41
NR1H4 Q96RI1 1/20 0.41
GAA P10253 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
MAPT P10636 1/20 0.40
FFAR1 O14842 1/20 0.40
LMNA P02545 1/20 0.40
MAOB P27338 1/20 0.39
PKM P14618 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853048 1.00 NLRP3 (0.44) NLRP3PRMT5PTGER1PTGER4PTGER3
SCHEMBL6035133 0.85 FFAR1 (0.48) PTGER1PTGER4PTGER3PTGER2MRGPRX4
SCHEMBL477979 0.83 PTGER4 (0.48) PRMT5PTGER1PTGER4PTGER3PTGER2
SCHEMBL29853178 0.81 PRMT5 (0.47) PRMT5PTGER1PTGER4PTGER3PTGER2
SCHEMBL23219214 0.81 PRMT5 (0.47) PRMT5PTGER1PTGER4PTGER3PTGER2
SCHEMBL7219075 0.80 NLRP3 (0.55) NLRP3L3MBTL1ALDH1A1GAAMAPT
SCHEMBL23218359 0.77 NLRP3 (0.48) NLRP3L3MBTL1ALDH1A1GAAMAPT
SCHEMBL5661211 0.77 TBXAS1 (0.53) PRMT5PTGER1PTGER4PTGER3PTGER2
SCHEMBL30676655 0.77 NLRP3 (0.48) NLRP3L3MBTL1ALDH1A1GAAMAPT
SCHEMBL8409150 0.76 MAOB (0.43) PTGER1PTGER4PTGER3PTGER2FFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB NLRP3 1028/4885PRMT5 4504/4885PTGER1 1339/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB NLRP3 279/4885PRMT5 4233/4885PTGER1 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.